NOX 5.00% 10.5¢ noxopharm limited

Ann: Interim NOX66 Radiotherapy Clinical Data, page-6

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 228 Posts.
    lightbulb Created with Sketch. 45
    At the bottom of every post on Hot Copper there is a box that must be ticked indicating ones “sentiment” towards the stock in question. We’ve all seen the four options available....  because without ticking one of them we cannot publish our post.

    SELL,   HOLD,  BUY,  NONE.

    For as long as I can remember I’ve ticked the same box.  NONE.  I’ve done this despite always having a strong opinion on a stock every time I’ve posted. In effect I’m forced to tell a little white lie.

    My problem is that I don’t believe I should have to give advice to anyone on what to do with their hard earned cash. It’s not my place, it’s not my money.... and it’s never seemed right. So I guess NONE is my least worst option.

    Now I understand that in the larger scheme of things this may been seen as a trivial matter.... and it certainly is. But for the first time I’ve been driven to get this annoying little self-inflicted  battle I have with myself, out into the open and off my chest.   Hmmm!.... that feels better already. (grin)

    So why bring up this “sentiment to buying” foible now

    Well on this occasion it comes from the first two posts in this thread from Harvet and  Smithy 169. They’ve both read the latest PR and have seen some merit in it. They’ve also wondered why such news has been seemingly down played. These lads have used the words “remarkable news” and “very positive”.

    Now Harvet and I have a bit of a track record in often taking exception to each others posts.... if that’s not too much of an understatement?  The reason on my part is well known  to some....  its the way he lauds one CEO (KZA) and derides the other CEO (NOX) particularly on their differing styles of presentation and keeping investors informed and educated.

    Well this time, the data in the rather understated press release,  seems to have sparked a positive response from my chosen sparring partner. Now I hope this doesn’t kick off another spat.... because surprisingly perhaps... I think I agree with him.

    The news is good. The data is still a bit early stage for some folks... and I might have  agreed with them.... if I had not followed the “abscopal response” story from the very beginning. The opportunity to harness this fairly rare effect response is taking real shape. The panel of top doctors in the US medical advisory panel who Dr Kelly has assembled seem to have also seen the merit in this DARRT programme. The recent gathering in Philadelphia was very enthusiastic and positive.

    So why the lack of any major volume  so far on the news?

    Well now we come back to the “Sentiment” topic.  The possible reasons are as many as there are folks with an “opinion”.  My personal view is that news like this often has a type of “slow burn” with the market. The mode of action is not widely well known. The data is early and interim.... although anyone who has followed the story will be well aware of the burgeoning prospects by now. And in addition.... some will not really know how this rare response effect fits into the wider picture.

    Well... for those of us who do.... this is good steady news. For those who don’t understand the story.... or are still unsure, then by all means wait and see what the market makes of this.  It’s for sure that there is much more data to come and I look forward to that. We’re told a multi national phase 2 study is being planned and prepared... and this section also got my complete attention....

    The meeting also led to a recommendation to extend the DARRT program into additional cancer types including pancreatic cancer, head and neck cancer and primary brain cancer, all cancers associated with aggressive cancers and poor survival outcomes, and where, like prostate cancer, immuno-oncology drugs are proving generally ineffective. The Company now will undertake a strategic review of these opportunities, with investigator-initiated studies and clinical study grants likely to be used to pursue such indications.”

    I suspect the market will digest this interim news and start to take a renewed interest. Whether it will start a new upturn in the share price is for each of us to decide for ourselves.

    So.... when you see that I’ve ticked the NONE box in the “Sentiment” section.... perhaps you will not take it too literally from now on.  (grin)

    Apples
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
10.5¢
Change
0.005(5.00%)
Mkt cap ! $29.22M
Open High Low Value Volume
10.0¢ 10.5¢ 10.0¢ $555 5.296K

Buyers (Bids)

No. Vol. Price($)
1 95000 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 151971 2
View Market Depth
Last trade - 15.18pm 22/11/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.